AstraZeneca's COVID-19 Vaccine Trial Delays May Worsen As FDA Widens Investigation

AstraZeneca Plc’s (NYSE: AZN) coronavirus vaccine development program could hit by further delays, as the Food and Drug Administration has widened the scope of its probe into the halted trial, Reuters reported Wednesday.What Happened: The federal agency is inquiring whether side effects similar to the one seen in the COVID-19 vaccine trial — transverse myelitis — also emerged in trials of other vaccines designed by Oxford University, AstraZeneca’s partner, Reuters said, citing people familiar with the matter. The vaccines reportedly under review use a modified adenovirus as a vector and target illnesses such as the Middle East Respiratory Syndrome and …read more

Source:: Yahoo Finance